Skip to main content
. 2021 Jan 4;27(8):1285–1293. doi: 10.1093/ibd/izaa349

Table 2.

Participant Characteristics Stratified According to the Presence or Absence of Disease Activity

Characteristic Inactive N = 141 Active N = 101 P
Age (years), mean (SD) 46.4 (15.4) 49.0 (14.0) 0.17
Women, n (%) 87 (61.7) 66 (65.4) 0.56
White, n (%) 122 (87.1) 84 (83.2) 0.39
>High school education, n (%) 100 (70.9) 70 (69.3) 0.79
Annual Income, n (%) 0.006
 <$50,000 22 (15.6) 33 (32.7)
 ≥$50,000 106 (75.2) 63 (62.4)
 Declined 13 (9.2) 5 (4.9)
IBD Subtype, n (%)
 Crohn’s disease 74 (52.5) 75 (74.3) <0.001
 Ulcerative colitis 67 (47.5) 26 (25.7)
Immune therapy, n (%)
 Any 106 (75.2) 76 (75.3) 0.99
 Biologic 36 (25.5) 41 (40.6) 0.013
 Oral corticosteroid 3 (2.1) 6 (5.9) 0.17
Irritable bowel syndrome, n (%) 27 (19.2) 34 (33.7) 0.01
HADS-D ≥ 11 4 (2.8) 12 (11.9) 0.005
HADS-A ≥ 11 16 (11.4) 24 (24.0) 0.009
HADS-D, mean (SD) 2.9 (3.1) 5.3 (3.9) <0.001
HADS-A, mean (SD) 5.6 (3.9) 7.4 (4.2) <0.001
Current smoker, n (%) 18 (12.8) 24 (23.8) 0.026
Physical comorbidity, n (%) 0.017
 0 55 (39.0) 23 (22.8)
 1 33 (23.4) 24 (23.8)
 ≥2 53 (37.6) 54 (53.5)